GW Pharmaceuticals has initiated a Phase Ib/IIa clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM). The company will conduct a 20-patient, multicenter, two-part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, as well as a double-blind, placebo-controlled phase with patients randomized to active or placebo, with a primary outcome measure of six-month progression free survival. The study objective is to...